NCT01245374View on ClinicalTrials.gov

Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents

PHASE4CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Growth Hormone DisorderGrowth Hormone Deficiency in ChildrenFoetal Growth ProblemSmall for Gestational AgeGenetic DisorderTurner SyndromeChronic Kidney DiseaseChronic Renal InsufficiencyDelivery Systems
Interventions
DEVICE

Norditropin NordiFlex®

Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice

Trial Locations (1)

92932

Novo Nordisk Investigational Site, Paris La Défense Cedex

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY